Status:
UNKNOWN
Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?
Lead Sponsor:
Ziv Hospital
Collaborating Sponsors:
Hillel Yaffe Medical Center
Conditions:
Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3. Studies rarely address th...
Detailed Description
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3. Studies rarely address th...
Eligibility Criteria
Inclusion
- 18 to 65 years of age,
- Chronic genotype 2,3 HCV infection, Traetment Naive
- Negative sero for HBV, HDV and HIV viral infections
- Absolute neutrophil count of \>1500 per cubic millimeter, a platelet count of \>90,000 per cubic millimeter
- Normal hemoglobin level
Exclusion
- Decompensated liver disease (cirrhosis with CP score \>9)
- Another cause of clinically significant liver disease
- Hepato cellular carcinoma
- Psychiatric Disorder
- Chronic heart failure
- Pregnant women
- Uncontrolled diabetes with retinopathy
- Arythmia
- Active CAD
- Positive sero for HBV, HDV and HIV viral infections or other autoimmune liver disease
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2012
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01146626
Start Date
August 1 2011
End Date
May 1 2012
Last Update
April 28 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Liver clinic
Hedera, Israel
2
Ziv medical center liver unit
Safed, Israel, Israel, 13100